Recently, it was reported that the TLR9 agonist PRINT-CpG was effective in promoting tumor regression in mouse models of non-small cell lung cancer [46], and the TLR7/8 agonist also has an antitumor effect in melanoma [47], which was consistent with this study. Here, TLR9 is linked to melanoma.